Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Michael Irizarry_2023
VIEWPOINTS

Michael Irizarry shares insights from the P-III clinical study of LEQEMBI, for the treatment of Alzheimer’s disease

Shots:Michael Irizarry, Senior VP of Clinical Research and Deputy Chief Clinical Officer, Alzheimer’s Disease and Brain Health at Eisai in a stimulating conversation with PharmaShotsMichael shares insights from the P-III clinical study Clarity AD of LEQEMBI for the treatment of Alzheimer’s diseaseThe study highlights that LEQEMBI treatment met the primary endpoint and…
November 27, 2023

Read more

Viewpoints_Michael Irizarry
VIEWPOINTS

Michael Irizarry, SVP, Clinical Research, Eisai Shares Insights from the Clinical Data of Lecanemab Presented at AAIC

Shots:Michael talked about the new data from its Alzheimer’s pipeline at the Alzheimer’s Association International (AAIC)Michael also highlighted the study design of the P-II & P-III trial evaluating lecanemabThe interview gives an understanding of  Eisai’s human health care (hhc) concept which provides innovative products with high unmet medical needs to target diseases…
December 14, 2022

Read more